Sunday, July 25, 2021

Vaccine for children by September: AIIMS Director Dr. Randeep Guleria

New Delhi: The director of AIIMS, Delhi Dr. Randeep Guleria has said that Bharat Biotech’s Covaxin can be approved for use on children by September 2021.

Dr. Guleria said, “The data will be available by September after the Phase II and III trials of Covaxin on children.

Besides, he said, if Pfizer-BioNtech is approved in India, then it can also be an alternative as a vaccine for children.

While the second wave of corona in the country is gradually weakening, on the other hand, speculations are also being made about the third wave. According to experts, the third wave of corona can knock in India soon. Along with this, some experts and studies are telling that children are more likely to be affected in the third wave. In the midst of all this, big information has come to the fore regarding the vaccine for children.

Dr. Guleria said that in AIIMS Patna and AIIMS Delhi, a trial of Covaxin on children is going on. This trial is for children between 2 to 12 years. On May 12, DCGI approved Bharat Biotech for Phase II and III trials on children.

READ ALSO:  Chanu Saikhom Mirabai wins silver in weightlifting, opens tally for India

However, Dr. Guleria denied that children are more likely to be affected in the third wave. He said that there is no reason to believe in this theory. Let us tell you that recently, WHO and AIIMS together did a sero survey.

READ ALSO:  Ulidih youth shoots his 17-year-old friend dead in Sakchi, arrested

According to the findings of this survey, children are not likely to be affected much more than adults. The study was conducted in five selected states with a proposed population of 10,000.

Along with this, Dr. Guleria also asked to consider opening children’s schools, although he said that we also have to ensure that educational institutions do not become super spreaders of Corona.

Leave a Reply

Read More

Comments

Recent

Subsribe Our Newsletter & get Free Daily News & Opinion updates!

Town Post

FREE
VIEW